ACY-738

Overview

ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC 50 of 1.7 nM; ACY-738 also inhibits HDAC1 , HDAC2 , and HDAC3 , with IC 50 s of 94, 128, and 218 nM.

Application

Products | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-19327
• CAS No.: 1375465-91-0
• Molecular Formula: C14H14N4O2
• Molecular Weight: 270.29
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (7.70 mM); Clear solution
• Availability: In-stock

Source

Original product source